Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 9/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.33 |
| ▸ | PGR | P06401 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | AGXT | P21549 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15289017 | 0.82 | RIPK1 (0.37) | IDO1NR3C1NR3C2RIPK1PGR | |
| SCHEMBL7667398 | 0.78 | IDO1 (0.37) | IDO1NR3C1NR3C2RIPK1PGR | |
| SCHEMBL7667396 | 0.78 | IDO1 (0.37) | IDO1RIPK1PTGS2AGXT | |
| SCHEMBL1704764 | 0.78 | IDO1 (0.48) | IDO1NR3C1NR3C2RIPK1PGR | |
| SCHEMBL4404016 | 0.78 | RIPK1 (0.46) | IDO1NR3C1NR3C2RIPK1AGXT | |
| SCHEMBL28781489 | 0.77 | IDO1 (0.36) | IDO1PTGS2AGXT | |
| SCHEMBL9969387 | 0.77 | IDO1 (0.56) | IDO1SLC6A4 | |
| SCHEMBL13020830 | 0.77 | IDO1 (0.43) | IDO1NR3C1NR3C2RIPK1SLC6A4 | |
| SCHEMBL12870197 | 0.76 | NR3C1 (0.36) | IDO1NR3C1NR3C2RIPK1PGR | |
| SCHEMBL15107551 | 0.76 | CA3 (0.52) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376431-B2 | Bis-quaternary cinchona alkaloid salts as asymmetric phase transfer catalysts | MERCK SHARP & DOHME CORP. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150031891-A1 | BIS-QUARTERNARY CINCHONA ALKALOID SALTS AS ASYMMETRIC PHASE TRANSFER CATALYSTS | MERCK SHARP & DOHME CORP. (US) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031891-A1 | BIS-QUARTERNARY CINCHONA ALKALOID SALTS AS ASYMMETRIC PHASE TRANSFER CATALYSTS | COASY, BCHE, CLK4 | IDO1 300/4885NR3C1 4555/4885NR3C2 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.